148 related articles for article (PubMed ID: 37126418)
21. Type I and III interferons are good markers to monitor COVID-19 pathophysiology.
Darif D; Ejghal R; Desterke C; Outlioua A; Hammi I; Lemrani M; Hilali F; Guessous F; Zaid Y; Akarid K
Cytokine; 2023 May; 165():156172. PubMed ID: 36924609
[TBL] [Abstract][Full Text] [Related]
22. Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation.
Zhang Q; Bastard P; Bolze A; Jouanguy E; Zhang SY; ; Cobat A; Notarangelo LD; Su HC; Abel L; Casanova JL
Med; 2020 Dec; 1(1):14-20. PubMed ID: 33363283
[TBL] [Abstract][Full Text] [Related]
23. More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients.
Joly C; Desjardins D; Porcher R; Péré H; Bruneau T; Zhang Q; Bastard P; Cobat A; Resmini L; Lenoir O; Savale L; Lécuroux C; Verstuyft C; Roque-Afonso AM; Veyer D; Baron G; Resche-Rigon M; Ravaud P; Casanova JL; Le Grand R; Hermine O; Tharaux PL; Mariette X
Front Immunol; 2023; 14():1250214. PubMed ID: 38077399
[TBL] [Abstract][Full Text] [Related]
24. A hybrid discrete-continuum model of immune responses to SARS-CoV-2 infection in the lung alveolar region, with a focus on interferon induced innate response.
Aristotelous AC; Chen A; Forest MG
J Theor Biol; 2022 Dec; 555():111293. PubMed ID: 36208668
[TBL] [Abstract][Full Text] [Related]
25. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.
Matuozzo D; Talouarn E; Marchal A; Zhang P; Manry J; Seeleuthner Y; Zhang Y; Bolze A; Chaldebas M; Milisavljevic B; Gervais A; Bastard P; Asano T; Bizien L; Barzaghi F; Abolhassani H; Abou Tayoun A; Aiuti A; Alavi Darazam I; Allende LM; Alonso-Arias R; Arias AA; Aytekin G; Bergman P; Bondesan S; Bryceson YT; Bustos IG; Cabrera-Marante O; Carcel S; Carrera P; Casari G; Chaïbi K; Colobran R; Condino-Neto A; Covill LE; Delmonte OM; El Zein L; Flores C; Gregersen PK; Gut M; Haerynck F; Halwani R; Hancerli S; Hammarström L; Hatipoğlu N; Karbuz A; Keles S; Kyheng C; Leon-Lopez R; Franco JL; Mansouri D; Martinez-Picado J; Metin Akcan O; Migeotte I; Morange PE; Morelle G; Martin-Nalda A; Novelli G; Novelli A; Ozcelik T; Palabiyik F; Pan-Hammarström Q; de Diego RP; Planas-Serra L; Pleguezuelo DE; Prando C; Pujol A; Reyes LF; Rivière JG; Rodriguez-Gallego C; Rojas J; Rovere-Querini P; Schlüter A; Shahrooei M; Sobh A; Soler-Palacin P; Tandjaoui-Lambiotte Y; Tipu I; Tresoldi C; Troya J; van de Beek D; Zatz M; Zawadzki P; Al-Muhsen SZ; Alosaimi MF; Alsohime FM; Baris-Feldman H; Butte MJ; Constantinescu SN; Cooper MA; Dalgard CL; Fellay J; Heath JR; Lau YL; Lifton RP; Maniatis T; Mogensen TH; von Bernuth H; Lermine A; Vidaud M; Boland A; Deleuze JF; Nussbaum R; Kahn-Kirby A; Mentre F; Tubiana S; Gorochov G; Tubach F; Hausfater P; ; ; ; ; ; ; ; ; ; Meyts I; Zhang SY; Puel A; Notarangelo LD; Boisson-Dupuis S; Su HC; Boisson B; Jouanguy E; Casanova JL; Zhang Q; Abel L; Cobat A
Genome Med; 2023 Apr; 15(1):22. PubMed ID: 37020259
[TBL] [Abstract][Full Text] [Related]
26. Type I interferons and SARS-CoV-2: from cells to organisms.
Bastard P; Zhang Q; Zhang SY; Jouanguy E; Casanova JL
Curr Opin Immunol; 2022 Feb; 74():172-182. PubMed ID: 35149239
[TBL] [Abstract][Full Text] [Related]
27. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia.
Philippot Q; Fekkar A; Gervais A; Le Voyer T; Boers LS; Conil C; Bizien L; de Brabander J; Duitman JW; Romano A; Rosain J; Blaize M; Migaud M; Jeljeli M; Hammadi B; Desmons A; Marchal A; ; ; Mayaux J; Zhang Q; Jouanguy E; Borie R; Crestani B; Luyt CE; Adle-Biassette H; Sene D; Megarbane B; Cobat A; Bastard P; Bos LDJ; Casanova JL; Puel A
J Clin Immunol; 2023 Aug; 43(6):1093-1103. PubMed ID: 37209324
[TBL] [Abstract][Full Text] [Related]
28. Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors.
Quarleri J; Delpino MV
Cytokine Growth Factor Rev; 2021 Apr; 58():55-65. PubMed ID: 33608189
[TBL] [Abstract][Full Text] [Related]
29. Immune response in SARS-CoV-2 infection: the role of interferons type I and type III.
Portela Sousa C; Brites C
Braz J Infect Dis; 2020; 24(5):428-433. PubMed ID: 32866437
[TBL] [Abstract][Full Text] [Related]
30. Examination of autoantibodies to type I interferon in patients suffering from long COVID.
Hansen KS; Jørgensen SE; Skouboe MK; Agergaard J; Schiøttz-Christensen B; Vibholm LK; Tolstrup M; Østergaard L; Leth S; Mogensen TH
J Med Virol; 2023 Sep; 95(9):e29089. PubMed ID: 37698062
[TBL] [Abstract][Full Text] [Related]
31. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2022; 13():840126. PubMed ID: 35359967
[TBL] [Abstract][Full Text] [Related]
33. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.
Dinnon KH; Leist SR; Schäfer A; Edwards CE; Martinez DR; Montgomery SA; West A; Yount BL; Hou YJ; Adams LE; Gully KL; Brown AJ; Huang E; Bryant MD; Choong IC; Glenn JS; Gralinski LE; Sheahan TP; Baric RS
Nature; 2020 Oct; 586(7830):560-566. PubMed ID: 32854108
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors.
Kumar A; Ishida R; Strilets T; Cole J; Lopez-Orozco J; Fayad N; Felix-Lopez A; Elaish M; Evseev D; Magor KE; Mahal LK; Nagata LP; Evans DH; Hobman TC
J Virol; 2021 Jun; 95(13):e0026621. PubMed ID: 34110264
[TBL] [Abstract][Full Text] [Related]
35. Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection.
Sohn SY; Hearing J; Mugavero J; Kirillov V; Gorbunova E; Helminiak L; Mishra S; Mackow E; Hearing P; Reich NC; Kim HK
mBio; 2021 Dec; 12(6):e0275621. PubMed ID: 34724828
[TBL] [Abstract][Full Text] [Related]
36. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.
Bastard P; Orlova E; Sozaeva L; Lévy R; James A; Schmitt MM; Ochoa S; Kareva M; Rodina Y; Gervais A; Le Voyer T; Rosain J; Philippot Q; Neehus AL; Shaw E; Migaud M; Bizien L; Ekwall O; Berg S; Beccuti G; Ghizzoni L; Thiriez G; Pavot A; Goujard C; Frémond ML; Carter E; Rothenbuhler A; Linglart A; Mignot B; Comte A; Cheikh N; Hermine O; Breivik L; Husebye ES; Humbert S; Rohrlich P; Coaquette A; Vuoto F; Faure K; Mahlaoui N; Kotnik P; Battelino T; Trebušak Podkrajšek K; Kisand K; Ferré EMN; DiMaggio T; Rosen LB; Burbelo PD; McIntyre M; Kann NY; Shcherbina A; Pavlova M; Kolodkina A; Holland SM; Zhang SY; Crow YJ; Notarangelo LD; Su HC; Abel L; Anderson MS; Jouanguy E; Neven B; Puel A; Casanova JL; Lionakis MS
J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33890986
[TBL] [Abstract][Full Text] [Related]
37. Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.
Schuhenn J; Meister TL; Todt D; Bracht T; Schork K; Billaud JN; Elsner C; Heinen N; Karakoese Z; Haid S; Kumar S; Brunotte L; Eisenacher M; Di Y; Lew J; Falzarano D; Chen J; Yuan Z; Pietschmann T; Wiegmann B; Uebner H; Taube C; Le-Trilling VTK; Trilling M; Krawczyk A; Ludwig S; Sitek B; Steinmann E; Dittmer U; Lavender KJ; Sutter K; Pfaender S
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35131898
[TBL] [Abstract][Full Text] [Related]
38. Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children.
Bucciol G; ; Meyts I
J Allergy Clin Immunol; 2023 Apr; 151(4):832-840. PubMed ID: 36841740
[TBL] [Abstract][Full Text] [Related]
39. Age-Related Expression of IFN-λ1
Gilbert C; Lefeuvre C; Preisser L; Pivert A; Soleti R; Blanchard S; Delneste Y; Ducancelle A; Couez D; Jeannin P
Front Immunol; 2021; 12():750279. PubMed ID: 34858406
[TBL] [Abstract][Full Text] [Related]
40. Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies.
Akbil B; Meyer T; Stubbemann P; Thibeault C; Staudacher O; Niemeyer D; Jansen J; Mühlemann B; Doehn J; Tabeling C; Nusshag C; Hirzel C; Sanchez DS; Nieters A; Lother A; Duerschmied D; Schallner N; Lieberum JN; August D; Rieg S; Falcone V; Hengel H; Kölsch U; Unterwalder N; Hübner RH; Jones TC; Suttorp N; Drosten C; Warnatz K; Spinetti T; Schefold JC; Dörner T; Sander LE; Corman VM; Merle U; ; Kurth F; von Bernuth H; Meisel C; Goffinet C
J Clin Immunol; 2022 Aug; 42(6):1111-1129. PubMed ID: 35511314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
